Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Baxter
Colorcon
Cantor Fitzgerald
Daiichi Sankyo
Cipla
McKinsey
US Department of Justice
McKesson
Express Scripts
Citi

Generated: February 19, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 020926

« Back to Dashboard

NDA 020926 describes RENAGEL, which is a drug marketed by Genzyme and is included in two NDAs. It is available from six suppliers. There is one patent protecting this drug and one Paragraph IV challenge. Additional details are available on the RENAGEL profile page.

The generic ingredient in RENAGEL is sevelamer hydrochloride. There are thirty-two drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the sevelamer hydrochloride profile page.
Summary for 020926
Tradename:RENAGEL
Applicant:Genzyme
Ingredient:sevelamer hydrochloride
Patents:0
Therapeutic Class:Genitourinary Agents
Formulation / Manufacturing:see details

Profile for product number 001

Active Rx/OTC/Discontinued:DISCNDosage:CAPSULE;ORALStrength403MG
Approval Date:Oct 30, 1998TE:RLD:No

Expired US Patents for NDA 020926

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Genzyme RENAGEL sevelamer hydrochloride CAPSULE;ORAL 020926-001 Oct 30, 1998 ➤ Sign Up ➤ Sign Up
Genzyme RENAGEL sevelamer hydrochloride CAPSULE;ORAL 020926-001 Oct 30, 1998 ➤ Sign Up ➤ Sign Up
Genzyme RENAGEL sevelamer hydrochloride CAPSULE;ORAL 020926-001 Oct 30, 1998 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Deloitte
Dow
UBS
Express Scripts
Farmers Insurance
Queensland Health
Daiichi Sankyo
Harvard Business School
Accenture

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot